MDR trending analysis guidance
This article was originally published in The Gray Sheet
FDA puts on hold an effort to develop a document to assist manufacturers in identifying trends in medical device reports. FDA staffers say problems have been encountered in developing guidance general enough to cover all situations. The agency announced it would develop the document in July 1992 ("The Gray Sheet" July 20, p. 3). Trend analysis will be required under MDR regs being finalized.
You may also be interested in...
House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”